Skip to main content
SpringerLink
Log in

Ropinirole versus levodopa in parkinson’s disease

  • Clinical Trials Report
  • Published:
Current Neurology and Neuroscience Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Jenner P: Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation. Neurology 2004, 62(1 suppl 1):S47-S55.

    PubMed  CAS  Google Scholar 

  2. Stocchi F, Olanow CW: Continuous dopaminergic stimulation in early and advanced Parkinson’s disease. Neurology 2004, 62(1 suppl 1):S56-S63.

    PubMed  CAS  Google Scholar 

  3. Hutton JT, Metman LV, Chase TN, et al.: Transdermal dopaminergic D(2) receptor agonist therapy in Parkinson’s disease with N-0923 TDS: a double-blind, placebo-controlled study. Mov Disord 2001, 16:459–463.

    Article  PubMed  CAS  Google Scholar 

  4. Metman LV, Gillespie M, Farmer C, et al.: Continuous transdermal dopaminergic stimulation in advanced Parkinson’s disease. Clin Neuropharmacol 2001, 24:163–169.

    Article  PubMed  CAS  Google Scholar 

  5. Parkinson Study Group: Effect of deprenyl on the progression of disability in early Parkinson’s disease. The Parkinson Study Group. N Engl J Med 1989, 321:1364–1371.

    Article  Google Scholar 

  6. Olanow CW, Calne D: Does selegiline monotherapy in Parkinson’s disease act by symptomatic or protective mechanisms? Neurology 1991, 42:13–26.

    Google Scholar 

  7. Parkinson Study Group: Mortality in DATATOP: a multicenter trial in early Parkinson’s disease. Parkinson Study Group. Ann Neurol 1998, 43:318–325.

    Article  Google Scholar 

  8. Parkinson Study Group: Pramipexole vs. levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group. JAMA 2000, 284:1931–1938.

    Article  Google Scholar 

  9. Parkinson Study Group: Dopamine transporter brain imaging to assess the effects of pramipexole vs. levodopa on Parkinson disease progression. JAMA 2002, 287:1653–1661.

    Article  Google Scholar 

  10. Marek K, Seibyl J: Beta-CIT scans without evidence of dopaminergic deficit (SWEDD) in the ELLDOPA-CIT and CALM-CIT study: long-term imaging assessment. Neurology 2003, 60(suppl 1):A293.

    Google Scholar 

  11. Ahlskog JE: Slowing Parkinson’s disease progression: recent dopamine agonist trials. Neurology 2003, 60:381–389.

    PubMed  Google Scholar 

  12. Parkinson Study Group: Does levodopa slow or hasten the rate of progression of Parkinson disease? The results of the ELLDOPA trial. Neurology 2003, 60(suppl 1):A80-A81.

    Google Scholar 

  13. Cervalo R, Piccini P, Bailey DL, et al.: 18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson’s disease. Synapse 2002, 43:201–207.

    Article  CAS  Google Scholar 

  14. Turjanski N, Lees AJ, Brooks DJ: Striatal dopaminergic receptor dysfunction in patients with restless legs syndrome. 18Fdopa and 11C-raclopride PET studies. Neurology 1999, 52:932–937.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. John C. Morgan MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kapil D. Sethi MD, FRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Morgan, J.C., Sethi, K.D. Ropinirole versus levodopa in parkinson’s disease. Curr Neurol Neurosci Rep 4, 274–276 (2004). https://doi.org/10.1007/s11910-004-0051-3

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11910-004-0051-3

Keywords

Search

Navigation